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INTRODUCTION 
Cystic Fibrosis (CF, MIM 219700) is the most common lethal genetic 
disorder among Caucasians (1: 3 000). It’s an autosomal recessive disease, 
caused by mutations in the CFTR gene, and its diagnosis is frequently 
delayed  due to the non-specificity of a wide variety of clinical symptoms, 
including chronic lung disease, pancreatic dysfunction, elevated chloride 
levels in sweat and male infertility. The elevation of immunoreactive 
trypsinogen (IRT) in the blood of CF newborns makes feasible the 
newborn screening (NBS) for this disease (Crossley et al., 1979), but IRT is 
a low specificity marker. 
Pancreatitis-associated protein (PAP) was also demonstrated to have 
elevated concentrations in CF newborns (Sarles et al., 1999) and several 
strategies including IRT as 1st marker and PAP or genetic analysis as 2nd or 
3rd tier tests, are still being tested and implemented in different countries. 
Although the advantages of CF NBS are considered clear, and most 
newborns in North America, Australasia and Europe are already being 
screened for CF, there’s yet no agreement regarding the best strategy to 
use. 
 In October 2013, a pilot study for CF NBS in 80 000 newborns was started, 
which intents to determine the best strategy for the Portuguese 
population.  
PATIENTS AND METHODS 
An IRT/PAP/IRT strategy is being used (Figure 1) and 52 000 newborns 
were already screened. 
RESULTS 
From the 52 000 newborns screened, 485 (0.93%) presented an 
increased IRT level. In 35 of these cases, IRT was higher than 150 
ng/mL and a 2nd sample was immediately requested.  
PAP determination was done for 450 newborns, from which 192 cases 
had increased levels, according to Figure 1.  From the 227 second 
samples (0.37% recall rate), eleven presented persistent elevated IRT 
levels and these newborns were sent to a specialized medical center 
for further evaluation (Table 1). 
In 2 cases (Table 1, cases 10 and 11) the sweat test revealed to be 
negative. 
Nine patients (Table 1, cases 1 to 9) were confirmed though positive 
sweat test or genetic analysis.  
All nine patients identified have at least one F508del allele and seven 
of them were homozygotes for this mutation.   
DISCUSSION AND CONCLUSIONS 
PAP determination, in combination with IRT determination, allowed 
us to considerably reduce the number of 2nd samples requisition 
(from 0.93% to 0.37%), and seems to be a valuable approach in the 
CF NBS strategy. 
According with these results, F508del mutation seems to be much 
frequent in our population than previously thought, which may 
indicate that a genetic approach based on F508del detection could 
also be interesting in our population. 
CF seems to have in Portugal  a  1: 5 700 approximate frequency. 
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Figure 1 -  Portuguese strategy for CF NBS 
Cases nº 
(sampling days) 
1st IRT 
(N<65ng/mL) 
PAP* 
2nd IRT 
(N<50ng/mL) 
Genotype 
1   (5d, 18d) 94 5,4 158 F508del/F508del 
2   (21d, --) 129 3,9 n.d. F508del/F508del 
3   (6d, 14d) 210 >8,8 287 F508del/? 
4   (23d, 28d) 190 >8,8 195 F508del/F508del 
5   (3d, 13d) 260 4,3 344 F508del/F508del 
6   (4d, 27d) 266 >8,8 360 F508del/F508del 
7   (5d, 15d) 443 >8,8 480 F508del/F508del 
 8   (4d, -----) 202 2,7 n.d. F508del/N1303K 
9   (2d, 5d) 101 >8,8 85 F508del/F508del 
10   (4d, 24d) 65 2,8 56 n.d. 
11   (4d, 18d) 68 2,3 67 n.d. 
*N<0,5ng/mL   if   IRT ≥100 ng/mL   or   N<1,6ng/mL   if   IRT< 100ng/mL 
Table 1 – Newborns sent to specialized medical center  
